NCT02753127 2023-11-15CanStem303CSumitomo Pharma America, Inc.Phase 3 Completed1,253 enrolled 18 charts
NCT02993731 2023-11-15CanStem111PSumitomo Pharma America, Inc.Phase 3 Completed1,134 enrolled 18 charts
NCT02130557 2021-05-18A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaPfizerPhase 3 Completed536 enrolled 24 charts 1 FDA
NCT00773747 2021-04-30Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)Merck Sharp & Dohme LLCPhase 3 Completed637 enrolled 15 charts
NCT01650805 2014-11-17Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)Ariad PharmaceuticalsPhase 3 Terminated307 enrolled 11 charts
NCT01064960 2012-12-04Therapeutic MRI-HIFU Ablation of Uterine Fibroids in a 3T MRI ScannerPhilips HealthcarePhase 3 Completed7 enrolled
NCT01009593 2012-09-10Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)AbbottPhase 3 Terminated1,035 enrolled